Nigeria has joined more than 100 other countries to participate in the World Health Organisation (WHO)’s “solidarity trial treatment” for COVID-19.
The arrangement is part of the efforts of the international health organisation’s effective treatment regimen and vaccine to combat coronavirus in the shortest possible time.
Minister of Health Dr. Osagie Ehanire, who announced this on Monday at the briefing by the Presidential Task Force (PTF) on COVID-19 in Abuja on Monday said: “Federal Government is cooperating with the WHO on treatment regimen solidarity trial with the following states enrolled; Lagos, Ogun, Kaduna, Sokoto, Kano and the Federal Capital Territory (FCT).”
The minister, however, did not state when the trial will begin and the modalities for it.
More than 1,200 patients have been randomised from the first five countries to evaluate the safety and efficiency of the drug combinations, it was learnt.
According to the agency, “the Solidarity Trial will compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19”. By enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival. Other drugs can be added based on emerging evidence.
The international health body added that “As of April 21 2020, over 100 countries are working together to find effective therapeutics as soon as possible, via the trial.
“The greater the number of participating countries, the faster results will be generated. WHO is facilitating access to thousands of treatment courses for the trial through donations from a number of manufacturers.
“Until there is sufficient evidence, WHO cautions against physicians and medical associations recommending or administering these unproven treatments to patients with COVID-19 or people self-medicating with them.”
The minister said Nigeria has conducted 27,078 COVID-19 tests with 4,399 cases in 34 states and the FCT. He gave the ratio of infection as 70 per cent for men to 30 per cent for women.